30 авг. 2021 г. · This study is conducted to see if ziltivekimab reduces the risk of having cardiovascular events (for example heart attack and stroke) in people with ...

15 окт. 2024 г. · This study is conducted to see if ziltivekimab reduces the risk of having cardiovascular events (for example heart attack and stroke) in people with ...

ZEUS is a global clinical study investigating if a new medicine called ziltivekimab reduces the risk of having cardiovascular events.

Novo Nordisk®. Results from the phase 2 trial RESCUE with ziltivekimab. Phase 3 CVOT trial ZEUS with ziltivekimab. Commercial execution and innovation.

20 авг. 2021 г. · The European Union Clinical Trials Register allows you to search for protocol and results information on EU/EEA interventional clinical trials.

5 авг. 2021 г. · With plans to initiate worldwide enrolment in late 2021, ZEUS will compare ziltivekimab to placebo among 6200 patients with Stages 3–4 CKD and ...

11 окт. 2024 г. · This study is conducted to see if ziltivekimab reduces the risk of having cardiovascular events (for example heart attack and stroke) in ...

The purpose of this study is to determine if the medication ziltivekimab reduces the risk of having cardiovascular events (for example heart attack and stroke)

ZEUS is a global clinical study investigating if a new medication reduces the risk of having cardiovascular events, (such as a heart attacks and strokes)

Participants will need to use the pre filled syringe to inject the study medicine into a skinfold once-monthly. The study is expected to last for up to 4 years.